The EIF4G1 gene and Parkinson's disease

Acta Neurologica Scandinavica

Volumn 132, Issue 2, 2015, Pages 73-78

  Deng, H ^a   Wu, Y ^a   Jankovic, J ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

EIF4G1; genetics; mutation; Parkinson's disease; variant

Indexed keywords

EUKARYOTIC TRANSLATION INITIATION FACTOR 4 GAMMA 1; INITIATION FACTOR 4G; UNCLASSIFIED DRUG;

DEGENERATIVE DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MOLECULAR PATHOLOGY; NEOPLASM; NEUROPATHOLOGY; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; GENETICS; MUTATION;

EUKARYOTIC INITIATION FACTOR-4G; HUMANS; MUTATION; PARKINSON DISEASE;

EID: 84935692859     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12397     Document Type: Review

References (42)

1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76.
2. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
3. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35.
4. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445-54.
5. Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol 2013;70:20-4.
6. Deng H, Gao K, Jankovic J. The VPS35 gene and Parkinson's disease. Mov Disord 2013;28:569-75.
7. Yan R, Rhoads RE. Human protein synthesis initiation factor eIF-4 gamma is encoded by a single gene (EIF4G) that maps to chromosome 3q27-qter. Genomics 1995;26:394-8.
8. Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 2010;11:113-27.
9. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009;136:731-45.
10. Yuan L, Song Z, Xu H et al. EIF4G1 Ala502Val and Arg1205His variants in Chinese patients with Parkinson disease. Neurosci Lett 2013;543:69-71.
11. Edwards YJ, Beecham GW, Scott WK et al. Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach. PLoS ONE 2011;6:e16917.
12. Nuytemans K, Bademci G, Inchausti V et al. Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology 2013;80:982-9.
13. Goyer C, Altmann M, Lee HS et al. TIF4631 and TIF4632: two yeast genes encoding the high-molecular-weight subunits of the cap-binding protein complex (eukaryotic initiation factor 4F) contain an RNA recognition motif-like sequence and carry out an essential function. Mol Cell Biol 1993;13:4860-74.
14. Long X, Spycher C, Han ZS, Rose AM, Muller F, Avruch J. TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation. Curr Biol 2002;12:1448-61.
15. Contreras V, Richardson MA, Hao E, Keiper BD. Depletion of the cap-associated isoform of translation factor eIF4G induces germline apoptosis in C. elegans. Cell Death Differ 2008;15:1232-42.
16. Foeger N, Kuehnel E, Cencic R, Skern T. The binding of foot-and-mouth disease virus leader proteinase to eIF4GI involves conserved ionic interactions. FEBS J 2005;272:2602-11.
17. Jang H, Boltz DA, Webster RG, Smeyne RJ. Viral parkinsonism. Biochim Biophys Acta 2009;1792:714-21.
18. Heman-Ackah SM, Hallegger M, Rao MS, Wood MJ. RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis. Front Mol Neurosci 2013;6:40.
19. Ryu I, Park JH, An S, Kwon OS, Jang SK. eIF4GI facilitates the MicroRNA-mediated gene silencing. PLoS ONE 2013;8:e55725.
20. Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011;89:398-406.
21. Lesage S, Condroyer C, Klebe S et al. EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants? Neurobiol Aging 2012;33:2233.e1-5.
22. Schulte EC, Mollenhauer B, Zimprich A et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease. Neurogenetics 2012;13:281-5.
23. Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005;57:933-4.
24. Gagliardi M, Annesi G, Tarantino P, Nicoletti G, Quattrone A. Frequency of the ASP620ASN mutation in VPS35 and Arg1205His mutation in EIF4G1 in familial Parkinson's disease from South Italy. Neurobiol Aging 2014;35:2422.e1-2.
25. Blanckenberg J, Ntsapi C, Carr JA, Bardien S. EIF4G1 R1205H and VPS35 D620N mutations are rare in Parkinson's disease from South Africa. Neurobiol Aging 2014;35:441-5.
26. Chen Y, Chen K, Song W et al. VPS35 Asp620Asn and EIF4G1 Arg1205His mutations are rare in Parkinson disease from southwest China. Neurobiol Aging 2013;34:1709.e7-8.
27. Li K, Tang BS, Guo JF et al. Analysis of EIF4G1 in ethnic Chinese. BMC Neurol 2013;13:38.
28. Nishioka K, Funayama M, Vilarino-Guell C et al. EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population. Parkinsonism Relat Disord 2014;20:659-61.
29. Sudhaman S, Behari M, Govindappa ST, Muthane UB, Juyal RC, Thelma BK. VPS35 and EIF4G1 mutations are rare in Parkinson's disease among Indians. Neurobiol Aging 2013;34:2442.e1-3.
30. Zhao Y, Ho P, Prakash KM et al. Analysis of EIF4G1 in Parkinson's disease among Asians. Neurobiol Aging 2013;34:1311.e5-6.
31. Fujioka S, Sundal C, Strongosky AJ et al. Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. Acta Neuropathol 2013;125:425-38.
32. Villa N, Do A, Hershey JW, Fraser CS. Human eukaryotic initiation factor 4G (eIF4G) protein binds to eIF3c, -d, and -e to promote mRNA recruitment to the ribosome. J Biol Chem 2013;288:32932-40.
33. Vosler PS, Gao Y, Brennan CS et al. Ischemia-induced calpain activation causes eukaryotic (translation) initiation factor 4G1 (eIF4GI) degradation, protein synthesis inhibition, and neuronal death. Proc Natl Acad Sci USA 2011;108:18102-7.
34. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007;69:1542-50.
35. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson's disease and cancer. Trends Neurosci 2005;28:348-52.
36. D'Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G. Parkinson's disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci 2009;1155:324-34.
37. Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS ONE 2012;7:e45183.
38. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H, Meese EU. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 2001;92:822-9.
39. Silvera D, Arju R, Darvishian F et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009;11:903-8.
40. Tu L, Liu Z, He X et al. Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol Cancer 2010;9:78.
41. Tucci A, Charlesworth G, Sheerin UM, Plagnol V, Wood NW, Hardy J. Study of the genetic variability in a Parkinson's Disease gene: EIF4G1. Neurosci Lett 2012;518:19-22.
42. Siitonen A, Majounie E, Federoff M, Ding J, Majamaa K, Singleton AB. Mutations in EIF4G1 are not a common cause of Parkinson's disease. Eur J Neurol 2013;20:e59.